Study of Lumateperone in the Treatment of Patients With Bipolar Mania

Completed · Phase 3 · Has a placebo group

Conditions studied: Bipolar Disorder, Manic

In brief

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Key facts

Study ID

NCT06462612

Run by

Intra-Cellular Therapies, Inc.

People needed

351

Starts

2024-07-17

Expected to finish

2026-05-20

Last updated by the study team

2026-07-24

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to provide written informed consent before the initiation of any study specific procedures;
• Male or female inpatient, between the ages of 18 and 75 years, inclusive;
• Meets the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM 5) criteria for bipolar I disorder with a current episode of mania or mania with mixed features with or without psychotic symptoms, as confirmed by a trained and Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT);
• YMRS total score ≥ 20 and a score of at least 4 on two of the following YMRS items: irritability, speech, content, and disruptive/aggressive behavior at Screening and Baseline;
• Hospitalized voluntarily before Screening or admitted to inpatient unit at Visit 1 with a primary diagnosis of mania but not > 14 days before Screening. Hospital admission must be a result of the current manic episode.

You may not qualify if…

• Has a current primary DSM 5 psychiatric diagnosis other than bipolar disorder. These include:
• Schizophrenia, schizoaffective disorder, or other psychotic disorders;
• Dementia or other cognitive disorders;
• Intellectual disability;
• Moderate or severe substance use disorder (excluding for nicotine);
• Experiencing first manic episode;
• In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during the course of his/her participation in the study or
• At Screening, the patient scores "yes" on Items 4 or 5 in the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening; or
• At Screening, the patient has had 1 or more suicidal attempts within 2 years prior to Screening; or
• At Baseline, the patient scores "yes" on Items 4 or 5 in the Suicidal Ideation section of the C-SSRS since the Screening Visit; or
• At Screening or Baseline, scores ≥ 4 on Item 10 (suicidal thoughts) on the rater administered Montgomery-Åsberg Depression Rating Scale (MADRS); or
• Considered to be an imminent danger to himself/herself or others.

Where it is running

• Clinical Site — Bentonville, Arkansas, United States
• Clinical Site — Little Rock, Arkansas, United States
• Clinical Site — Anaheim, California, United States
• Clinical Site — Cerritos, California, United States
• Clinical Site — Orange, California, United States
• Clinical Site — Torrance, California, United States
• Clinical Site — Hialeah, Florida, United States
• Clinical Site — Miami, Florida, United States
• Clinical Site — Miami, Florida, United States
• Clinical Site — Miami, Florida, United States
• Clinical Site — Miami Lakes, Florida, United States
• Clinical Site — Miami Lakes, Florida, United States
• Clinical Site — Tampa, Florida, United States
• Clinical Site — West Palm Beach, Florida, United States
• Clinical Site — Atlanta, Georgia, United States
• Clinical Site — Stockbridge, Georgia, United States
• Clinical Site — Chicago, Illinois, United States
• Clinical Site — Chicago, Illinois, United States
• Clinical Site — Gaithersburg, Maryland, United States
• Clinical Site — Glen Oaks, New York, United States
• Clinical Site — Cincinnati, Ohio, United States
• Clinical Site — Richardson, Texas, United States
• Clinical Site — Burgas, Bulgaria
• Clinical Site — Kazanlak, Bulgaria
• Clinical Site — Plovdiv, Bulgaria

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.